

ASHLEY A. LEECH

Vanderbilt University School of Medicine
ashley.leech@vanderbilt.edu | X: @ashleyleech

ACADEMIC APPOINTMENT

Vanderbilt University School of Medicine 2018-
Assistant Professor, Department of Health Policy

POST-DOCTORAL TRAINING

Tufts University School of Medicine July 2016 – Aug. 2018
Center for the Evaluation of Value and Risk in Health (CEVR)
Post-Doctoral Fellow in Health Economics/Decision Science

EDUCATION

Boston University Aug. 2012 – May 2016
PhD in Health Services Research

University of Oxford Sept. 2007 – July 2008
MS in International Relations/African Studies
Dissertation: Distinction

Lycoming College Aug. 2003 – May 2007
BA in Political Science/English Literature
Phi Beta Kappa & Sigma Tau Delta
Honors College
Magna Cum Laude

American University Aug. 2005 – Aug. 2006
American Government
Legislative Intern, Arlen Specter
Summa Cum Laude

FUNDED RESEARCH

2020-2015 NIH/NIDA (1 K01 DA050740, Leech)
Total: \$860,390
“Advancing Treatment Outcomes for Pregnant Women with Opioid Use Disorder”
Funding period: 04/01/2020-03/31/2025
Role: Principal Investigator, 9.00 calendar months

2024-2025 Vital Strategies, Bloomberg Philanthropies and CDC Foundation (Graves)
Total: \$231,475
“Health Economics Modeling Workshop”
Funding period: 08/01/2024-06/30/2025
Role: Co-investigator, 1.2 calendar years

2022-2023 Vital Strategies, Bloomberg Philanthropies and CDC Foundation (Graves)
Total: \$151,547
“Health Economics Modeling Workshop”
Funding period: 08/01/2022-06/30/2023
Role: Co-investigator, 1.2 calendar years

- 2024-2025 NIH/NIDA R01 Supplement; Univ. of Pittsburgh (R01DA055585-S1, Donahue)
Total: \$100,000
“Improving Racial Equity in Opioid Use Disorder Treatment in Medicaid”
Funding period: 03/01/2024-06/30/2025
Role: Co-investigator, 1.2 calendar years
- 2019-2024 NIH/NINDS (1 R01 NS113171, Trevathan),
Total: \$856,096 (Yr 1: DC), \$1,138,378 (Yr 1: Total)
“Bridging the Childhood Epilepsy Treatment Gap in Africa (BRIDGE)”
Funding period: 07/01/2019-06/30/2024
Role: Co-investigator, 1.2 calendar years
- 2022-2023 NIH/NICHHD (P50HD106446-GR013778, Kannankeril/Edwards)
Total pilot grant: \$40,000
Maternal/pediatric precision therapeutics: “Maternal Mortality and Overdose in Opioid-Vulnerable and Opioid-Dependent Pregnant Individuals”
Funding period: 01/01/2022-07/31/2023
Role: Principal Investigator
- 2018-2019 NIH/NIDA (R01 DA045729, Patrick)
Total: \$474,596
“Improving Access to Treatment for Women with Opioid Use Disorder”
Funding period: 4/15/2018 – 01/31/2022
Role: Co-investigator, 1.2 calendar years
- 2018-2020 CDC/Tennessee Department of Health (GR1959823, Limper)
Total: \$93,600
“Evaluation of TDOH’s statewide efforts to improve screening and reduce morbidity and mortality related to cancers across the state.”
Funding period: 8/1/2018 – 6/30/2020
Role: Co-investigator, 0.6 calendar years

PEER-REVIEWED PUBLICATIONS

45. **Leech AA**, Garbett S, Yu HA, McNeer E, Bharadwaj R, Linas BP, Graves J, Young J, Su L, Martin PR, Ward MJ, Ellingham MN, Kozhimannil KB, Samuels LR, Patrick SW. Optimizing Pregnancy and Birth Outcomes in the US: A Cost-Effectiveness Analysis of Treatment for Opioid Use Disorder. *Under Review: Annals of Internal Medicine*
44. Reese, TJ, Wiese AD, **Leech AA**, Domenico H, McNeer E, Davis SE, Matheny M, Wright A, Patrick SW. Adapting a Risk Prediction Tool for Neonatal Opioid Withdrawal Syndrome. *Pediatrics*. In Press
43. **Leech AA**, Zhu J, Martin M, Garbett S, Graves J. Modeling Disability-Adjusted Life Years for Policy and Decision Analysis. *Medical Decision Making*. In Press
42. Fry CE, Li Y, Horta M, **Leech AA**. Rates of Prescribing Contraceptives among Women Treated for Opioid Use Disorder, 2016-2021. *JAMA Internal Medicine*. In Press
41. Fang Y, Jeffery AD, Patrick SW, Young J, Raffi E, Harder GM, Osmundson SS, Phillippi J, **Leech AA**. Association of Opioid Use Disorder-Related Service Trajectories During Pregnancy and Postpartum Health Service Use: A Group-Based Multi-Trajectory Modeling Study. *Journal of Addiction Medicine*. In Press
40. Reese, TJ, Padi-Adjirackor NA, Griffith KN, Steitz B, Patrick SW, **Leech AA**, Wiese AD, Wright A, Shan MV, Ancker JS. Comparative Effectiveness of Buprenorphine Adherence with

Telemedicine versus In-person for Rural and Urban Patients. *Journal of the American Pharmacists Association*. 2024 Dec 28; 102318. <https://doi.org/10.1016/j.japh.2024.102318>

39. Fry CE, Jeffrey AD, Horta M, Li Y, Osmundson SS, Phillippi J, Schirle L, Morgan JR, **Leech AA**. Changes in Postpartum Opioid Prescribing After Implementation of State Opioid Prescribing Limits. *JAMA Health Forum*. 2024 Nov 1; 5(11): e244216. doi: 10.1001/jamahealthforum.2024.4216
38. Hart K, Medvecz AJ, Vaidya A, Dusetzina S, **Leech AA**, Wiese AD. Opioid and non-opioid analgesic regimens after fracture and risk of serious opioid-related events. *Trauma Surgery Acute Care Open*. 2024 July 14; 9(1): e001364. doi: 10.1136/tsaco-2024-001364. eCollection 2024
37. Spieker AJ, Adgent MA, Osmundson SS, Phillips SE, Mitchel E, **Leech AA**, Grijalva CG, Wiese AD. The impact of different strategies for modeling associations of medications at low doses and health outcomes: a simulation study and practical application to postpartum opioid use. *American Journal of Epidemiology*. 2024 Jun 21; 00, 1-9; <https://doi.org/10.1093/aje/kwae147>
36. Morgan JR, **Leech AA**. Commentary on Schmidt *et al.*: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals. *Addiction*. 2024 April 3; 1-2; <https://doi.org/10.1111/add.16495>
35. Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, Baeten JM, Liu A, Hoover KW, Celum C, Grinsztejn B, Morris S, Wheeler DP, Mayer KH, Golub SA, Bekker LG, Diabaté S, Hoornenborg E, Myers J, **Leech AA**, McCormack S, Chan PA, Sweat M, Matthews LT, Grant R, the Global F/TDF PrEP Study Team. HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies. *Clinical Infectious Diseases*. 2024 March 14; ciae143: 1-23; <https://doi.org/10.1093/cid/ciae143>
34. Marrazzo J, Tao L, Becker M, **Leech AA**, Taylor AW, Ussery F, Kiragu M, Reza-Paul S, Myers J, Bekker LG, Yang J, Carter C, de Boer M, Das M, Baeten JM, Celum C. HIV Preexposure Prophylaxis with Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women. *JAMA*. 2024 March 1; 331(11): 930-937; doi:10.1001/jama.2024.0464
33. Bosworth OM, Padilla-Azain MC, Adgent MA, Spieker AJ, Wiese AD, Pham A, **Leech AA**, Grijalva CG, Osmundson SS. Prescription Opioid Exposure During Pregnancy and Risk of Spontaneous Preterm Delivery. *JAMA Network Open*. 2024 February 14; 7(2): e2355990; doi:10.1001/jamanetworkopen.2023.55990
32. Clifford CM, Askew N, Smith D, Iniguez J, Smith A, House MD, **Leech AA**. Prenatal aneuploidy screening in a low-risk Hispanic population: price elasticity and cost-effectiveness. *AJOG Global Reports*. 2024 February 1; 4(1): 100293; <https://doi.org/10.1016/j.xagr.2023.100293>
31. **Leech AA**, McNeer E, Stein BD, Richards MR, McElroy T, Dupont WD, Patrick SW. County-level Factors and Treatment Access Among Insured Women with Opioid Use Disorder. *Medical Care*. 2023 December 1; 61(12): 816-821; doi: 10.1097/MLR.0000000000001867
30. Sampson C, **Leech AA**, Garcia-Lorenzo B. Opportunity costs in health care: cost-effectiveness thresholds and beyond. Editorial article, *Front. Health Serv., Sec. Cost and Resource Allocation*. 2023 October 26; Vol 3: 1293592; <https://doi.org/10.3389/frhs.2023.1293592>
29. **Leech AA**, Roberts AA, Dusetzina SB, Lai P, Morgan JR, Patrick SW. Out-of-pocket costs, and buprenorphine persistence among privately insured adults initiating treatment for opioid use

- disorder. *JAMA Internal Medicine*. 2023 August 7; e232826; doi: 10.1001/jamainternmed.2023.2826
28. Boos EW, Horta M, Thompson I, Dusetzina SB, **Leech AA**. Trends in the use of mifepristone for medical management of early pregnancy loss, 2016-2020. *JAMA*. 2023 Jul 21; doi: 10.1001/jama.2023.13628
 27. Grossarth, S, Osmundson SS, Wiese AD, Phillips SE, Pham A, **Leech AA**, Patrick SW, Spieker AJ, Grijalva CG, Adgent MA. Maternal Opioid Use Disorder and the Risk of Postneonatal Infant Mortality. *JAMA Pediatrics*. 2023 July 1; 177(7): 675-683; doi: 10.1001/jamapediatrics.2023.1047
 26. Richards M, **Leech AA**, Stein BD, Patrick SW. Prevalence of buprenorphine providers requiring cash payment from insured women seeking opioid use disorder treatment. *Medical Care*. 2023 Jun 1; 61(6): 377-383; doi: 10.1097/MLR.0000000000001851
 25. Baig K, Dusetzina SB, Kim DD, **Leech AA**. Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead. *N Engl J Med*. 2023 March 11; 388(11): 961-963; doi: 10.1056/NEJMp2300516
 24. Wisotzkey AK, **Leech AA**, Graves AR, Lwelu CC, Pourali SP, Osmundson SS. Obstetrical clinician opioid prescribing perspectives after cesarean delivery in Tennessee. *American Journal of Obstetrics and Gynecology, Maternal-Fetal Medicine (AJOG-MFM)*. 2022 December 9; 5(3): 100835; doi: <https://doi.org/10.1016/j.ajogmf.2022.100835>
 23. **Leech AA**, Lin PJ, D’Cruz B, Parson SK, Lavelle TA. Family Spillover Effects – Are Economic Evaluations Misrepresenting the Value of Healthcare Interventions to Society? *Applied Health Economics and Health Policy*. 2022 August 23; 21(1): 5-10; doi: 10.1007/s40258-022-00755-8
 22. Sampson C, Zamora B, Watson S, Cairns J, Chalkidou K, Cubi-Molla P, Devlin N, García-Lorenzo B, Hughes DA, **Leech AA**, Towse A. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy. *Applied Health Economics and Health Policy*. 2022 Jun 7; 20(5): 651-667; doi: 10.1007/s40258-022-00730-3
 21. Richards M, **Leech AA**, Stein BD, Buntin MB, Patrick SW. Medicaid Prevalence and Addiction Treatment Access Disparities for Women with Opioid Use Disorder. *Health Services Research*. 2022 April; 57(2): 422-429; doi: 10.1111/1475-6773.13920
 20. Tang LA, Jeffery AD, **Leech AA**, Osmundson SS, Schirle L, Phillippi JC, PhD. A Comparison of Methods to Identify Antenatal Substance Use Within Electronic Health Records. *American Journal of Obstetrics & Gynecology MFM*. 2021 November 19; 4(2); <https://doi.org/10.1016/j.ajogmf.2021.100535>
 19. Webb, P, Goodarz D, Masters WA, Rosettie KL, **Leech AA**, Cohen JT, Blakstad M, Kranz S, Mozaffarian D, the Global Nutrition and Policy Consortium. Modelling the Potential Cost-Effectiveness of Food-Based Programs to Reduce Malnutrition. *Global Food Security*. 2021 June; Vol 29; doi: 10.1016/j.gfs.2021.100550
 18. Nguyen JT, Cole AL, **Leech AA**, Wood WA, Dusetzina SB. [Author’s reply]: Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia. *Value in Health*. 2021 July; 24(7): 1086-1087; <https://doi.org/10.1016/j.jval.2020.12.025>

17. Nguyen JT, Cole AL, **Leech AA**, Wood WA, Dusetzina SB. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia. *Value in Health*. 2020 October; 23(10): 1292-1299; doi: 10.1016/j.jval.2020.05.019
16. **Leech AA**, Christiansen C, Linas BP, Jacobsen DM, Morin I, Drainoni M-L. Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. *PLOS One*. 2020 September 3; 15(9): e0238375; <https://doi.org/10.1371/journal.pone.0238375>
15. Patrick SW, Richards M, McNeer E, Dupont W, Buntin MB, Martin PR, Davis MM, Davis C, Hartman K, **Leech AA**, Lovell KS, Stein BD, Cooper WO. Association of Pregnancy and Insurance Status with Treatment Access for Opioid Use Disorder. *JAMA Network Open*. 2020 August 14; 3(8): e2013456; doi:10.1001/jamanetworkopen.2020.13456
14. Lessing NL, Zuckerman SL, Lazaro A, **Leech AA**, Leidinger A, Rutabasibwa N, Shabani HK, Mangat HS, Härtl R. Cost-effectiveness of operating on traumatic spinal injuries in low-middle income countries: a preliminary report from a major East African referral center. *Global Spine Journal*. 2020 August 17: 1-9; doi: 10.1177/2192568220944888
13. **Leech AA**, Biancarelli DL, Aaron E, Miller ES, Coleman J, Anderson PL, Nkwihoreze H, Condron B, Sullivan M. HIV Pre-exposure Prophylaxis (PrEP) for Conception among HIV Serodiscordant Couples in the United States: A Cohort Study. *AIDS Patient Care STDs*. 2020 July 6; 34(7): 295-302; doi: 10.1089/apc.2020.0005
12. **Leech AA**, Cooper MO, McNeer E, Scott TA, Patrick SW. Neonatal Abstinence Syndrome in the United States, 2004-2016. *Health Affairs*. 2020 May; 39(5): 764-767; doi: 10.1377/hlthaff.2019.00814
11. **Leech AA**, Neumann PJ, Cohen JT, Jagasia M, Dusetzina SB. Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S. *Oncologist*. 2020 May 9; 25(7): e1117-e1119; doi: 10.1634/theoncologist.2020-0025
10. **Leech AA**, Kim DD, Cohen JT, Neumann PJ. Are Low and Middle-Income Countries Prioritising High-Value Healthcare Interventions? *BMJ Global Health*. 2020 February 4; 5(2): e001850; doi: 10.1136/bmjgh-2019-001850
9. Lin P-J, D’Cruz B, **Leech AA**, Neumann PJ, Aigbogun MS, Oberdhan D, Lavelle T. Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions. *Pharmacoeconomics*. 2019 April; 37(4): 597-608; doi: 10.1007/s40273-019-00788-3
8. **Leech AA** and Dusetzina SB. Cost-Effective but Unaffordable: The CAR T Conundrum. *J Natl Cancer Inst*. 2019 July 1; 111(7): 644-645; doi: 10.1093/jnci/djy195
7. **Leech AA**, Burgess J, Sullivan M, Kuohung W, Horný M, Drainoni M-L, Christiansen C, Linas BP. The Cost-Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention During Conception in the United States. *AIDS*. 2018 Nov 28; 32(18): 2787-2798; doi: 10.1097/QAD.0000000000002014
6. Drainoni M-L, Biancarelli DL, **Leech AA**, Sullivan M, Bazzi AR. Implementing a Pre-Exposure Prophylaxis Intervention for Safer Conception among HIV Serodiscordant Couples: Recommendations for Health Care Providers. *J Health Dispar Res Pract*. 2018 Summer; 11(2): 19-33
5. **Leech AA**, Kim DD, Cohen JT, Neumann PJ. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. *Value in Health*. 2018 Jul, Epub 2018 Feb 21; 21(7): 759-761; doi: 10.1016/j.jval.2017.12.016

4. Thokala P, Ochalek J, **Leech AA**, Tong T. Cost-Effectiveness Thresholds: The Past, the Present and the Future. *Pharmacoeconomics*. 2018 May; 36(5): 509-522; doi: 10.1007/s40273-017-0606-1
3. **Leech AA**, Bortoletto P, Christiansen C, Drainoni M-L, Linas BP, Roeca C, et al. Assessing access to assisted reproductive services for serodiscordant couples with human immunodeficiency virus infection. *Fertil Steril*. 2018 Mar, Epub Feb 7; 109(3): 473-477; doi: 10.1016/j.fertnstert.2017.11.039
2. Bazzi AR, **Leech AA**, Biancarelli DL, Sullivan M, Drainoni M-L. Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States. *AIDS Patient Care STDs*. 2017 Aug, Epub Jul 18; 31(8): 348-355; doi: 10.1089/apc.2017.0098
1. Curtis M, El Ayadi A, Mkumba G, Butrick E, **Leech A**, Geissler J, et al. Association between severe obstetric hemorrhage and HIV status. *Int J Gynaecol Obstet*. 2014 Apr, Epub Jan 14;125(1): 79-80; doi: 10.1016/j.ijgo.2013.10.010

INVITED TALKS (SELECTED)

- 2025 *Decisions for Two: The Scope & Limits of Decision Analysis in Pregnancy*. Center for Chronic Disease Research and Policy. Department of Medicine, University of Chicago, January 29, 2025
- 2024 *Treatment for Opioid Use Disorder: Optimizing Pregnancy and Birth Outcomes*. Beth Israel Deaconess Medical Center/Harvard Newborn Health Services and Epidemiology Seminar, January 4, 2024
- 2023 *Integrating pregnancy, postpartum, and birth outcomes into a discrete event simulation model of opioid use disorder treatment (Oral)*. 45th Annual North American Meeting of the Society for Medical Decision Making; Philadelphia, PA. October 22-25, 2023
- 2023 *Cost-Effectiveness Analysis and its Role in Health Policy*. Vanderbilt University School of Medicine, Division of Internal Medicine and Public Health, October 16, 2023
- 2023 *Treatment for Opioid Use Disorder: Optimizing Pregnancy and Birth Outcomes*. Harvard Pilgrim Health Care Institute and Harvard Medical School, Division of Child Health Research and Policy (CHERP), June 26, 2023
- 2023 *Improving Birth Outcomes through Economic Evaluations (Oral)*. Pediatric Academic Societies Meeting; Washington, DC. April 27-May 1, 2023
- 2022 *Treatment for Opioid Use Disorder: Advancing Maternal and Birth Outcomes*. University of Michigan, Susan B. Meister Child Health Evaluation and Research (CHEAR) Center, November 8, 2022
- 2022 *Treatment for Opioid Use Disorder: Advancing Maternal and Birth Outcomes*. Vanderbilt University School of Medicine, Vanderbilt Pediatric Research Conference, November 14, 2022
- 2022 *Opioid use disorder and birth outcomes: The impact of preterm birth and weight on long-term survival, quality of life, and healthcare costs (Oral)*. Society for Medical Decision Making 44th Annual North American Meeting; Seattle, Washington. October 23-26, 2022
- 2021 *Advancing Treatment Outcomes for Pregnant Individuals with Opioid Use Disorder*. University of California at Davis, UC Davis Center for Health Care Policy and Research, May 5, 2021

- 2021 *Cost-effectiveness Analysis and its Role in Health Policy*. Vanderbilt University School of Medicine, Vanderbilt Internal Medicine Residency Program: Learning Communities Series, April 16, 2021
- 2021 *Treatment for Opioid Use Disorder: Reducing Barriers to Engaging in Care (Oral)*. Rx Drug Abuse & Heroin Summit; Virtual. April 5-8, 2021
- 2020 *Barriers to Accessing Medications for Opioid Use Disorder Among Pregnant Women*. AcademyHealth 2020 Annual Research Meeting; Virtual. July 28-August 6, 2020.
- 2019 *Cost-effectiveness Analysis and Comparative Effectiveness Analysis*. Vanderbilt University School of Nursing, Health Services Research Track, June 27, 2019
- 2017 *Cost-effectiveness thresholds in published cost-per-DALY studies (Oral)*. 12th World Congress of the International Health Economics Association; Boston, Massachusetts, July 2017
- 2016 *Assessing Access to Assisted Reproductive Services for HIV Serodiscordant Couples (Oral)*. American Society for Reproductive Medicine Scientific Congress; Salt Lake City, Utah, Oct. 2016

TEACHING

Vanderbilt University

- | | |
|---|-------|
| Instructor, Decision Analysis in Medicine and Public Health | 2019- |
| Co-Instructor, Health Economics Modeling Workshop, in partnership with Vital Strategies and the CDC Foundation; approximately 30 participants from 15 countries | 2024 |
| Co-Instructor, Health Economics Modeling Workshop, in partnership with Vital Strategies and the CDC Foundation; approximately 30 participants from 15 countries | 2022 |
| Guest lecturer, Public Health Practice: Systems Thinking | 2019 |

Boston University

- | | |
|---|-----------|
| Guest lecturer, Introduction to Cost-Effectiveness Analysis | 2017 |
| Lecturer/Teaching Assistant, Comparative Health Systems and Policy in Industrialized and BRIC Countries | 2014-2016 |
| Teaching Assistant, Health Care Delivery Systems: Issues and Innovations | 2015 |
| Lecturer, Leadership, and Management in Public Health | 2015 |
| Teaching Assistant, American Government for Public Health Students | 2013 |

RESEARCH SUPERVISION

- | | |
|--|------|
| Chen Liu, PhD student, thesis advisor, Department of Health Policy, Vanderbilt University School of Medicine | 2024 |
| Markov Minanov, MPH student, thesis advisor, Department of Health Policy, Vanderbilt University School of Medicine; Project: Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement: Opioid Prescribing Practices in a Commercially Insured Cohort | 2023 |

Ahra Kim, PhD student, thesis advisor, Department of Health Policy, Vanderbilt University School of Medicine	2022
Anna Wisotzkey, MPH student, thesis advisor, Department of Health Policy, Vanderbilt University School of Medicine; Project: Obstetric provider perspectives on opioid prescribing after childbirth	2020
Ben Osher, medical student, research immersion project, Vanderbilt University School of Medicine; Project: Cost-effectiveness of Abdominal Aortic Aneurysm Screening	2019
Tamee Livermont, MPH student, thesis advisor, Department of Health Policy Vanderbilt University School of Medicine; Project: Assessment of postpartum contraceptive use in the 2016-2017 CDC PRAMS data	2019
Sadie Sommer, MPH student, thesis advisor, Department of Health Policy Vanderbilt University School of Medicine; Project: Maternal Mortality Committee Reports: A comparative review	2019
Caitlin Clifford, PGY3, OBGYN Resident, Tufts Medical Center; Project: Cost-effectiveness analysis on aneuploidy screening among pregnant Hispanic women in the United States	2018
Mathias Schreiner, Master's 4+1 student, Vanderbilt University; practicum experience in health policy related to cost-effectiveness analyses and pregnancy	2018
Nicole Quinones, MPH student, thesis committee, Vanderbilt University School of Medicine; Project: Postpartum contraceptive use in the 2011-2015 NSFG	2018

PROFESSIONAL SERVICE AND AFFILIATIONS

Professional Affiliations:

Society for Medical Decision Making (SMDM)

- Chair, MDM Teaching Interest Group, 2019-present
- Education Committee Member, 2021-present
- Finance Committee Member, 2023-present

AcademyHealth | International Health Economics Association (iHEA)

University Service and Affiliations:

Ph.D. Comprehensive Exams Committee | Ph.D. Advisory Committee | MPH Review Committee | Health Policy Grand Rounds | Vanderbilt University's Center for Child Health Policy

Editorial Activities – Journal Reviewer:

JAMA Network Open [Statistical Reviewer], Annals of Internal Medicine, NEJM, Health Affairs, Value in Health, Health Services Research, Women's Health Issues, Journal of Patient-Reported Outcomes, Health and Quality of Life Outcomes, MDM Policy and Practice, WHO Bulletin, BMJ Open

OTHER SKILLS AND INTERESTS

Computer SAS, SQL, R, C#